A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Status:
Recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational
drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid
malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1)
that is found on hematologic tumor cells. ROR1 has been shown to play a role in cell
signaling that cause leukemia and lymphoma cells to grow and survive. ROR1 is rarely found on
healthy cells.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, San Diego
Collaborators:
California Institute for Regenerative Medicine (CIRM) Oncternal Therapeutics, Inc